News
By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...
Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...
Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...
The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...
6d
MedPage Today on MSNFor Your Myeloma Patients: Are You a Candidate for Autologous Stem Cell Transplant?Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging ...
This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.
Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...
Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...
STOBOCLO ® (denosumab-bmwo) and OSENVELT ® (denosumab-bmwo) are approved by FDA for all indications of PROLIA ® (denosumab) and XGEVA ® (denosumab) respectively [1], [2] STOBOCLO and OSENVELT, among ...
England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological cancer multiple myeloma, in the latest stage of the medicine's renaissance.
Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how ...
CAR T-cell therapy is starting to enter the treatment conversations sooner with patients with multiple myeloma, according to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results